The Role of Lipoic Acid in the Treatment of Diabetic Polyneuropathy

1997 ◽  
Vol 29 (4) ◽  
pp. 1025-1054 ◽  
Author(s):  
Gerreke Ph. Biewenga ◽  
Guido R. M. M. Haenen ◽  
Aalt Bast
2021 ◽  
Vol 17 (3) ◽  
pp. 258-270
Author(s):  
N.A. Kravchun ◽  
I.P. Dunaieva ◽  
P.P. Kravchun

The paper presents an analysis of current literature data on the use of the R-enantiomer of α-lipoic acid as an antihypertensive treatment in patients with hypertension and metabolic syndrome. An analysis of the literature was carried out on its use as an antiinflammatory agent in inflammatory diseases. Currently, a very important aspect of researches is the possibility of using R-α-lipoic acid as a micronutrient and therapeutic agent for the treatment of diabetic polyneuropathy and neurodegenerative di­seases, especially Alzheimer’s disease, carbohydrate metabolism disorders and metabolic syndrome. Lipoic acid has now become an important ingredient in multivitamin formulas, anti-aging supplements. R-α-lipoic acid is a metabolic antioxidant, its molecule contains a dithiolane ring in oxidized form, this ring has the ability to cleave with formation of dihydrolipoic acid. And since α-lipoic acid, a physiological form of thioctic acid, is a strong antioxidant that relieves the symptoms of diabetic neuropathy, the literature review analyzed data from various authors on the antioxidant effects of the R-enantiomer of α-lipoic acid and found that it had strong antioxidant effects, and its dose of 300 mg is bioequivalent to 600 mg of racemic α-lipoic acid. As presented in a sufficient number of analyzed sources, the biological role of lipoic acid is quite diverse. It is important to determine the exact causal relationship between lipoic acid and its immediate cellular targets. Lipoic acid can have a number of important and diverse physiological effects on the stimulation of neurohormonal function and, thus, indirectly affect multiple cellular signaling pathways in peripheral tissues.


Diabetes Care ◽  
2003 ◽  
Vol 26 (3) ◽  
pp. 770-776 ◽  
Author(s):  
A. S. Ametov ◽  
A. Barinov ◽  
P. J. Dyck ◽  
R. Hermann ◽  
N. Kozlova ◽  
...  

Biochemistry ◽  
1981 ◽  
Vol 20 (16) ◽  
pp. 4555-4560 ◽  
Author(s):  
Larry R. Stepp ◽  
Dennis M. Bleile ◽  
Donald K. McRorie ◽  
Flora H. Pettit ◽  
Lester J. Reed

2010 ◽  
Vol 6 ◽  
pp. 848-853 ◽  
Author(s):  
Seyfettin Gumus ◽  
Orhan Yucel ◽  
Mehmet Gamsizkan ◽  
Ayse Eken ◽  
Omer Deniz ◽  
...  

2020 ◽  
Vol 12 (4) ◽  
pp. 113-118
Author(s):  
V. A. Golovacheva ◽  
I. A. Strokov

The most common form of peripheral nervous system damage in diabetes mellitus is distal symmetric sensorimotor polyneuropathy (DSSMPN). Chronic hyperglycemia, dyslipidemia, and impaired microcirculation are considered to be the key mechanisms for the development of DSSMPN, but its pathogenesis is still unclear and continues to be studied. The paper analyzes the issues of diagnosis of DSSMPN and the effective principles of patient treatment. It also discusses the use of alpha-lipoic acid (ALA) as a drug for the pathogenetic treatment of DSSMPN and describes the results of clinical trials of its treatment with ALA preparations.


Sign in / Sign up

Export Citation Format

Share Document